You make a great point. No doubt, the company comes cheap now if Pfizer wants to make its move.
Amarin is priced as if bankruptcy is a possibility. Wall Street also is pricing it as if sales will never take off, not in the U.S., and not in Europe either. And Wall Street probably also believes it's just a matter of time before generics take 40 percent or 50 percent of the U.S. market, despite only having a skinny label. Is Europe priced in? No. China? No. And perhaps for good reason. Eighteen months after sales started in Canada, there are only a few thousand scripts sold.
But current share price can change in an instant. If Amarin announced that Pfizer was going to begin touting Vascepa in the U.S. as it is in Canada, the share price would leap to double digits in a day. And takeover speculation would greatly accelerate. Same would happen if word leaked out that Pfizer was in talks to buy Amarin.
Then a double or tripling of the share price in a takeover announcement would not seem that unreasonable.
News 
Market Data 
Discover 
